Treating Patients With Traumatic Chondral Lesions With Autologous Bone Marrow Cells Derived Engineered Tissues

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-26

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to establish the safety profile of the autologous engineered osteochondral tissues (eOCT) in treating traumatic chondral lesions in patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autologous Cell-derived Tissue Engineered Cartilage for Repairing Articular Cartilage Lesions

NCT02770209

Cartilage Diseases

UNKNOWN NA

The Biomechanical Outcomes of Autologous Chondrocyte Implantation

NCT06921889

Chondral Defect

RECRUITING

Tissue Engineered Cartilage to Repairing Articular Cartilage Defects

NCT07094100

Cartilage Injury OA Knee

NOT_YET_RECRUITING NA

Safety and Efficacy Study of Cells Sheet-Autologous Chondrocyte Implantation to Treat Articular Cartilage Defects

NCT01694823

Osteochondritis Osteochondritis Dissecans Joint Diseases

UNKNOWN PHASE1/PHASE2

Autologous Chondrocyte Transplantation For Articular Cartilage Regeneration

NCT01503970

Tear; Knee, Cartilage, Articular

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TCL-aMSC- eOCT is a single arm first-in-human trial designed to establish the safety profile of autologous tissue engineered osteochondral tissue (eOCT) in patients with traumatic chondral lesions. Patient selection will base on medical records, especially MRI results, and other criteria. Patient enrollment and informed consent will be conducted at the baseline visit. In a pre-treatment visit, bone marrow aspiration will be conducted to harvest autologous bone marrow for mesenchymal stem/stromal cells (MSCs) isolation and subsequent eOCT manufacturing. Cartilage lesion will be repaired in the treatment visit by delivering eOCT through arthroscopic surgery roughly 13 weeks after the pre-treatment visit. Rehabilitation will be conducted post-implantation. Multiple follow-up visits will be conducted up to 24 months post-implantation, data including adverse events, clinical and functional scoring and blood tests will be collected during each follow-up visit. Radiological assessment such as magnetic resonance imaging (MRI) will be conducted regularly until the end of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Cartilage Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

eOCT Treatment

In a pre-treatment visit, bone marrow aspiration will be conducted to harvest autologous bone marrow for mesenchymal stem/stromal cells (MSCs) isolation for subsequent eOCT manufacturing. Cartilage lesion will be addressed in the treatment visit by delivering eOCT through arthroscopic surgery roughly 13 weeks after the pre-treatment visit.

Group Type EXPERIMENTAL

eOCT implantation

Intervention Type COMBINATION_PRODUCT

eOCT is regarded as an Advanced Therapy Product (ATP).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

eOCT implantation

eOCT is regarded as an Advanced Therapy Product (ATP).

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: Subjects who are in the age range of 18-60 years
* Location: Single symptomatic cartilage defect on medial or lateral femoral condyle
* Size \& Containment: Contained single focal cartilage lesion of size \~1-4 cm square
* Grading: Cartilage damage ICRS/Outerbridge grade III/IV reaching subchondral bone (As diagnosed by MRI)
* Conservative treatments failed (for \> 4 months)

Exclusion Criteria

Disease Factor---

* Previous cartilage repair surgery (OATS or ACI/MACI) in the index knee
* Previous injectional treatments such as HA/PRP/stem cell in the index knee within 3 months before informed consent
* Presence of a clinically relevant patellofemoral cartilage lesion in the index knee (patella/trochlea/both)
* Inflammatory joint disease (specific or non-specific arthritis)
* Metabolic diseases (gout or rheumatism)
* Advanced Osteoarthritis (Radiologically apparent degenerative joint disease in the target knee as determined by Kellgren \& Lawrence Grade \>2)
* Osteochondritis dissecans
* Multiple or uncontained lesions as detected by MRI or arthroscopy
* Uncorrected ligament deficiency
* Uncorrected varus or valgus malalignment exceeding 5°
* Ongoing Infection or skin diseases at target knee joint
* Significant meniscal loss

Patient Factor---

* Subjects who are not able or not willing to give voluntary, written informed consent to participate in this study
* Skeletal immaturity
* Female subjects who are pregnant or lactating
* Body mass index \> 30 kg/m2
* Malignancy
* Steroid therapy by systemic or intra-articular route within the last 60 days before informed consent or intramuscular or oral steroids within the last 30 days before informed consent
* Contraindications to MR imaging
* Drug addiction (including narcotic, anesthetic or alcohol addiction)
* Patients who are at higher risk for post-surgical bleeding (e.g., bleeding disorder; taking anticoagulants except low dose aspirin
* Patients who are at higher risk for post-surgical infection (e.g., taking immunosuppressants; have a severe infection or a history of serious infection)
* Known allergy to porcine/bovine collagen
* Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee
* Patients with human immunodeficiency virus, hepatitis, or syphilis
* Any clinically significant or symptomatic vascular or neurologic disorder of the lower extremities
* Poor general health condition as judged by investigator
* Unable to do follow up

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No